ptcl

This study was to detect the expression of survivin in PTCL , and analyze its correlation to clinical features and prognosis of PTCL .

本研究通过检测周围T细胞淋巴瘤肿瘤组织survivin表达情况，探讨其表达与临床预后的关系。

Cox regression model showed that survivin was an independent poor prognostic index of PTCL .

多因素分析显示survivin表达是周围T细胞淋巴瘤的独立预后指标。

Open-chain Boundary Conditions for PtCl Complex and Its Exciton

PtCl络合物的开链边界条件和激子

Once in a conference , someone said to me , [ the PTCL bid ] was a failure .

他表示：在一次会议上曾有人对我说，（对巴基斯坦电信的竞购）是一次失败。

Objective To retrospectively analyze the treatment outcomes and prognostic factors of na - sal and nasopharyngeal peripheral T cell lymphomas ( PTCL ) patients .

目的对发生于鼻腔和鼻咽部位的外周T细胞淋巴瘤的临床特点、治疗和预后情况进行回顾分析，并探讨治疗方法的改进。

Objective To analyse the pathomorphology and clinical behavior of panniculitic T cell lymphoma ( PTCL ) and to study the classification and name of PTCL .

目的分析皮下脂膜炎性T细胞淋巴瘤的病理形态和生物学行为特点，并对其分类命名作一探讨。

BACKGROUND & OBJECTIVE : Peripheral T-cell lymphoma ( PTCL ) accounts for about 10 % - 15 % of non-hodgkin 's lymphomas ( NHL ), usually associated with short clinical course and poor prognosis .

背景与目的：周围T细胞淋巴瘤（peripheralT-Celllymphoma，PTCL）约占NHL的10%～15%，临床表现进展快、预后差。

Objective : The purpose of the study was to improve the early clinical diagnosis of panniculitic T-cell lymphoma ( PTCL ) by analyzing the clinical manifestations , pathological features and the biologic behavior in 10 cases of PTCL .

目的：研究10例脂膜炎性T细胞淋巴瘤的临床病理形态和生物学行为特点，为临床早期诊断提供依据。

Background and purpose : Peripheral T-cell lymphoma ( PTCL ) are more common in Asia and China . Its biological behavior is different from B-cell NHL . It showed chemoresistance with a high incidence of relapse and poor prognosis .

背景与目的：对于亚洲和中国较为常见的PTCL，其生物学行为与B细胞NHL不同，往往表现为化疗疗效不佳，病情迁延，容易复发，预后不良。

The subtypes of T-cell lymphoma were as follows : peripheral T-cell lymphoma ( PTCL 24.3 % ), T-lymphoblastic lymphoma ( T-LBL 5.5 % ) and anaplastic large cell lymphoma ( ALCL 2.2 % ) .

T细胞淋巴瘤中最常见的是外周T细胞淋巴瘤（PTCL）（24.3%），其次是T淋巴母细胞淋巴瘤（T-LBL）（5.5%），间变大细胞淋巴瘤（ALCL）（2.0%）。